On March 9, 2022 Catamaran Bio, Inc., a biotechnology company developing off-the-shelf chimeric antigen receptor (CAR)-NK cell therapies to treat cancer, reported that the company will present preclinical efficacy data for its CAT-179 program, an allogeneic solid tumor CAR-NK cell therapy, at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2022, being held in New Orleans, Louisiana, April 8-13, 2022 (Press release, Catamaran Bio, MAR 9, 2022, View Source [SID1234609821]). CAT-179 is an allogeneic, cryopreserved HER2-targeted CAR-NK cell therapy engineered using Catamaran’s TAILWIND platform.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the poster presentation are as follows:
Presentation Title: Allogeneic natural killer cells engineered to express HER2 CAR, interleukin 15 and TGF beta dominant negative receptor effectively control HER2+ tumors
Session Title: Adoptive Cell Therapy 1
Session Date & Time: Sunday, April 10, 2022, from 1:30 p.m. – 5:00 p.m. CT
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 36
Abstract Number: 555
The abstract is now available on the AACR (Free AACR Whitepaper) conference website.